Business
Notice of IMC Shareholder Presentation
Notice of IMC Shareholder Presentation.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\nSkinBioTherapeutics plc (\"SkinBioTherapeutics\" or the \"Group\" or the \"Company\")\nPresentation on Superdrug Commercial Agreement\nvia Investor Meet Company platform\n \n27 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, will be providing a short presentation to shareholders on Thursday 3 July 2025 at 11am BST about the recently signed exclusive UK commercial agreement with Superdrug Stores plc, one of the UK's leading beauty and health retailers, related to its AxisBiotix™ food supplements to alleviate the symptoms of inflammatory skin conditions.\nThe presentation will be open to all existing and potential SkinBioTherapeutics shareholders. Investors who already follow SkinBioTherapeutics on the Investor Meet Company (IMC) platform will be invited automatically. Investors can sign up to Investor Meet Company for free Here.\nThe Company intends to hold an IMC shareholder presentation at a later date for a pre-close trading update.\n-Ends- \nFor more information please contact:\n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nSimon Hewitson, COO\n \n\n\n+44 (0) 191 495 7325\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\nSam Butcher\nPatrick Weaver\n \n\n\n+44 (0) 020 7496 3000\n \n\n\n\n\nVigo Consulting (financial press)\nRozi Morris\n \n\n\n+44 (0) 20 7390 0230\[email protected]\n \n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements that harness the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, a food supplement to alleviate the symptoms of inflammatory skin conditions, is sold directly and via Amazon, and will be sold via an exclusive UK commercial deal with Superdrug Stores plc later in 2025.\nThe Group is also acting as a consolidator and is making acquisitions in complemen...